Exploratory study on the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers in patients with moderate to severe plaque-type psoriasis treated with subcutaneous secukinumab (300 mg) during a 16 week open-label run-in phase followed by a 16 week randomized, double-blind, placebo-controlled withdrawal phase.
Overall design
Psoriasis patients received 300 mg subcutaneous secukinumab during a 16 week open-label run-in phase followed by 16 week randomized, double-blind, placebo-controlled withdrawal phase
Less...
More...